No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company's efforts are directed toward treating various hematological malignancies and solid tumors across China and the United States. Its robust pipeline includes several key candidates: CT053, an autologous CAR-T product, is currently in a pivotal Phase II trial in China for relapsed/refractory multiple myeloma. Additionally, CT041, another autologous CAR-T, is undergoing Phase Ib/II clinical trials for advanced gastric/gastroesophageal junction and pancreatic cancers in China, and Phase Ib trials for comparable indications in the U.S. CARsgen is also advancing CT011, an autologous CAR-T candidate, through Phase I for patients with Glypican-3 positive advanced hepatocellular carcinoma, and CT032, an autologous CAR-T, in Phase I/II for B cell Non-Hodgkin's lymphoma in China. Furthermore, its pipeline features AB011, a humanized monoclonal antibody in Phase I for CLDN18.2 positive solid tumors in China, as well as CT017, an autologous Glypican-3-targeted CAR-T for hepatocellular carcinoma, and other promising therapies for solid tumors.
www.carsgen.comNo one on the platform currently holds 2171.HK.
No tracked institution reports a position in 2171.HK as of their last filing.
No one on the platform has traded 2171.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 218.7% | |||||
| Profit Margin % | -77.9% | |||||
| Free Cash Flow Margin % | -193.4% | |||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $306M | +157.6% | $-0.27 | $-0.44–$-0.07 | — | 3 |
| 2027 | $660M | +115.3% | $-0.10 | $-0.37–$0.11 | — | 3 |
| 2028 | $1.4B | +105.1% | $0.56 | $-0.25–$1.41 | — | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-18 | $-0.22 | $-0.15 | +31.6% |
| 2026-03-06 | $-0.16 | $-0.04 | +71.4% |
| 2025-08-14 | $-0.44 | $-0.15 | +65.0% |
| 2025-03-18 | $-0.43 | $-0.86 | -102.5% |
| 2024-08-28 | $-0.28 | $-0.68 | -142.3% |
| 2024-03-26 | $-0.97 | $-0.68 | +29.5% |
| 2023-08-22 | $-0.50 | $-0.73 | -47.6% |
| 2023-03-21 | $-0.97 | $-1.06 | -9.3% |
| $12.73 |
| -4.86% |
| $10.7B |
| — |
| 2157.HKLepu Biopharma Co., Ltd. | $3.98 | +0.00% | $7.2B | — |
| 2256.HKAbbisko Cayman Limited | $8.51 | -2.24% | $6.1B | — |
Source: Financial Modeling Prep · peers by sector/industry